4 completed, 2 recruiting, 1 enrolling by invitation, 1 not yet recruiting. 4 Phase 2, 3 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Not applicable | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Vasomotor Symptoms (VMS): new trials by email Literature Review of Vasomotor Symptoms (VMS) trials Research Report on Vasomotor Symptoms (VMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women Waning Moon - Menopause, Vasomotor Symptoms (VMS) | Not applicable | Not yet recruiting | University of Utah | 30 | 2026-08-01 | 2026-08-27 |
| Intra Ovarian Muse Cell Injection for Perimenopause Symptom Relief and Ovarian Function Restoration (MUSE-OVARY) Perimenopause, Perimenopause-Related Depression | Enrolling by invitation | Healing Hope International | 12 | 2026-06-01 | 2026-04-06 | |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| Impact of Lean Pork on Endothelial Function in Perimenopause Pork Diet, Plant Diet - Cardiovascular Outcome, Overweight and Obese Women | Not applicable | Recruiting | Pennington Biomedical Research Center | 30 | 2025-08-01 | 2026-09-22 |
| Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women JDS-HF3.0 - Hot Flashes, Hot Flash | Not applicable | Completed | Bonafide Health | 112 | 2024-05-24 | 2026-02-12 |
| Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor Q-122, Placebo - Vasomotor Symptoms (VMS) | Phase 2 | Completed | Que Oncology | 132 | 2018-10-24 | 2021-07-23 |
| Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms MT-8554 - Vasomotor Symptoms (VMS) | Phase 2 | Completed | Tanabe Pharma America, Inc. | 190 | 2018-04-18 | 2026-01-23 |
| Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen oral capsule of Q-122 - Vasomotor Symptoms (VMS) | Phase 1 | Completed | Que Oncology | 21 | 2014-01-10 | 2020-02-28 |
| Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS) AR08, Placebo - Vasomotor Symptoms (VMS) | Phase 2 | Terminated | Arbor Pharmaceuticals, Inc. | 32 | 2014-01-01 | 2015-12-09 |
Hot Flashes (4) · Multiple Endocrine Neoplasia Type 1 (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Endocrine System Diseases (1) · Overweight (1) · Primary Ovarian Insufficiency (1) · Prostatic Neoplasms (1)
Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Neoplasms (3) · Neoplasms by Site (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Endocrine Gland Neoplasms (2) · Genetic Diseases, Inborn (2) · Genital Diseases (2) · Multiple Endocrine Neoplasia (2) · Neoplasms, Multiple Primary (2) · Neoplastic Syndromes, Hereditary (2) · Urogenital Diseases (2) · Adnexal Diseases (1) · Body Weight (1) · Breast Diseases (1)
N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine (2) · Diet, Plant-Based (1)
Que Oncology (2) · Arbor Pharmaceuticals, Inc. (1) · Bonafide Health (1) · Healing Hope International (1) · Pennington Biomedical Research Center (1) · Shehzad Basaria, M.D. (1) · Tanabe Pharma America, Inc. (1) · University of Utah (1)
United States (6) · Australia (1) · Mexico (1) · New Zealand (1)
Dr. Jonatha Leicher, MD: Regenerative Medicine (1) · Hannah E Cabre, PhD, RDN (1) · Rob Crombie (1) · Shehzad S Basaria, MD (1)
R34AT013448 (1)